Cat. No.: HY-B0763

Ibudilast

(Synonyms: KC-404; AV-411; MN-166)

10 Cited Publications

Customer Review

Based on 10 publication(s) in Google Scholar

Ibudilast (KC-404; AV-411; MN-166) is a cyclic AMP phosphodiesterase (PDE) inhibitor. Ibudilast has platelet anti-aggregatory effects. Ibudilast can be used for the research of asthma for its inhibitory effects on tracheal smooth muscle contractility. Ibudilast may be a useful neuroprotective and anti-dementia agent counteracting neurotoxicity in activated microglia.

For research use only. We do not sell to patients.

Purity: 99.87%
CAS No.: 50847-11-5
Formula: C₁₄H₁₈N₂O
Molecular Weight:230.31

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Ibudilast Chemical Structure

CAS No.: 50847-11-5

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
- Clinical Trial
Chemical Information
Publications (10)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

IC₅₀ & Target

phosphodiesterase^[1]

All Phosphodiesterase (PDE) Isoforms :

In Vitro

Ibudilast (1~100 μM; 24 hours; microglia) suppresses both IL-1β and IL-6 production at 100 μM, and significantly suppresses TNF-α production at 10 and 100 μM^[1].
Ibudilast (1~100 μM; 48 hours; neuronal cells) significantly increases the neuronal survival rate. Ibudilast (1~100 μM; 48 hours; microglia) inhibits the production of superoxide and NO^[1].
Ibudilast upregulates the production of IL-10 in a dose-dependent manner. Ibudilast increases NGF mRNA and protein levels and GDNF and NT-4 mRNA expression. Ibudilast decreases the apoptotic changes observed in the neuronal cells in a dose-dependent manner^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

Microglia
Concentration:

1~100 μM
Incubation Time:

24 hours
Result:

Suppressed both IL-1β and IL-6 production at 100 µM, and significantly suppresses TNF-α production at 10 and 100 µM.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 50847-11-5
Appearance Solid
Molecular Weight 230.31
Formula C₁₄H₁₈N₂O
Color White to off-white
SMILES

CC(C)C(C1=C2C=CC=CN2N=C1C(C)C)=O
Synonyms

KC-404; AV-411; MN-166
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (10)

All WBCell Imaging/Staining

Sort by:

Journal Impact Factor

Nat Commun

Spatially-restricted inflammation-induced senescent-like glia in multiple sclerosis and patient-derived organoids. [Abstract]

2025 Sep 26;16(1):8477. PMID: 41006208
Brain

Repurposing ibudilast to mitigate Alzheimer's disease by targeting inflammation. [Abstract]

2023 Mar 1;146(3):898-911. PMID: 35411386
Biomed Pharmacother

Immune modulatory and vascular protective effects of Ibudilast in post-stroke inflammation. [Abstract]

2025 Oct 11:192:118638. PMID: 41076947
Biomedicines

Characterization of a Clinically and Biologically Defined Subgroup of Patients with Autism Spectrum Disorder and Identification of a Tailored Combination Treatment. [Abstract]

2024 Apr 30;12(5):991. PMID: 38790952
Toxicol Appl Pharmacol

Neuroprotective effects of ibudilast against tacrolimus induced neurotoxicity. [Abstract]

2022 Aug 15:449:116112. PMID: 35688184
Addict Biol

Ibudilast-Mediated Suppression of Neuronal TLR4 in the Prefrontal Cortex Mitigates Methamphetamine-Induced Neuroinflammation and Addictive Behaviours. [Abstract]

2025 Apr;30(4):e70033. PMID: 40237256

Ibudilast purchased from MedChemExpress. Usage Cited in: Addict Biol. 2025 Apr;30(4):e70033. [Abstract]

Expression levels of TLR4, p‐NF‐κB and IL‐6 in the prefrontal cortex following treatment with 3 mg/kg and 10 mg/kg Ibudilast.

Ibudilast purchased from MedChemExpress. Usage Cited in: Addict Biol. 2025 Apr;30(4):e70033. [Abstract]

Expression of TLR4 in neurons, microglia and astrocytes following treatment with 3 and 10 mg/kg Ibudilast.
Photochem Photobiol

Resatorvid-based Pharmacological Antagonism of Cutaneous TLR4 Blocks UV-induced NF-κB and AP-1 Signaling in Keratinocytes and Mouse Skin. [Abstract]

2016 Nov;92(6):816-825. PMID: 27859308
Biochem Biophys Rep

Effect of phosphodiesterase inhibitors on platelet function. [Abstract]

2025 Jun 26:43:102115. PMID: 40678798
Rapid Commun Mass Spectrom

Equine metabolic investigation of the phosphodiesterase-4 inhibitor ibudilast as a potential performance enhancer. [Abstract]

2024 Dec 15;38(23):e9916. PMID: 39307998
bioRxiv

2021 Apr 8.

Solvent & Solubility

In Vitro:

DMSO : ≥ 140 mg/mL (607.88 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.3420 mL

21.7099 mL

43.4197 mL

5 mM

0.8684 mL

4.3420 mL

8.6839 mL

10 mM

0.4342 mL

2.1710 mL

4.3420 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.67 mg/mL (11.59 mM); Clear solution

This protocol yields a clear solution of ≥ 2.67 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (26.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.67 mg/mL (11.59 mM); Clear solution

This protocol yields a clear solution of ≥ 2.67 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (26.7 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.67 mg/mL (11.59 mM); Clear solution

This protocol yields a clear solution of ≥ 2.67 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (26.7 mg/mL) to 900 μL Corn oil, and mix evenly.

Protocol 4

Add each solvent one by one: 5% DMSO 40% PEG300 5% Tween-80 50% Saline

Solubility: ≥ 2.5 mg/mL (10.85 mM); Clear solution

Protocol 5

Add each solvent one by one: 5% DMSO 95% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (10.85 mM); Clear solution

Protocol 6

Add each solvent one by one: 1% DMSO 99% Saline

Solubility: 0.5 mg/mL (2.17 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (281 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Mizuno T, et al. Neuroprotective role of phosphodiesterase inhibitor ibudilast on neuronal cell death induced by activated microglia. Neuropharmacology. 2004 Mar;46(3):404-11. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	4.3420 mL	21.7099 mL	43.4197 mL	108.5493 mL
	5 mM	0.8684 mL	4.3420 mL	8.6839 mL	21.7099 mL
	10 mM	0.4342 mL	2.1710 mL	4.3420 mL	10.8549 mL
	15 mM	0.2895 mL	1.4473 mL	2.8946 mL	7.2366 mL
	20 mM	0.2171 mL	1.0855 mL	2.1710 mL	5.4275 mL
	25 mM	0.1737 mL	0.8684 mL	1.7368 mL	4.3420 mL
	30 mM	0.1447 mL	0.7237 mL	1.4473 mL	3.6183 mL
	40 mM	0.1085 mL	0.5427 mL	1.0855 mL	2.7137 mL
	50 mM	0.0868 mL	0.4342 mL	0.8684 mL	2.1710 mL
	60 mM	0.0724 mL	0.3618 mL	0.7237 mL	1.8092 mL
	80 mM	0.0543 mL	0.2714 mL	0.5427 mL	1.3569 mL
	100 mM	0.0434 mL	0.2171 mL	0.4342 mL	1.0855 mL

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Ibudilast

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Drug Repurposing Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

Pyroptosis Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Alzheimer's Disease Compound Library

Neuroprotective Compound Library

Neurodegenerative Disease-related Compound Library

Rare Diseases Drug Library

Anti-Colorectal Cancer Compound Library

Protein-protein Interaction Inhibitor Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Coagulation and Anti-coagulation Compound Library

Heterocyclic Compound Library

Off-patent Drug Library

Metabolic Enzyme Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Chinese Baijiu Compound Library

Publications Citing Use of MedChemExpress (MCE) Ibudilast

All Phosphodiesterase (PDE) Isoforms

Biological Activity

Chemical Information

Publications (10)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Ibudilast Related Classifications

Cat. No.: HY-B0763